Session 6: How I Treat Double Relapsed/Refractory CLL

Co-Chair(s)

• 

  Jennifer Brown, MD, PhD

  Director, CLL Center, and Institute Physician; Worthington Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
  Dana-Farber Cancer Institute, Harvard Medical School
  Boston, Massachusetts, United States
• JS

  John Seymour, MBBS, PhD, FRACP

  Director, Department of Haematology
  Peter MacCallum Cancer Centre & Royal Melbourne Hospital
  Melbourne, Victoria, Australia

Presentations:

• 09:25 - 09:40 CEST

  Who Becomes/Are Double Refractory Patients?
  

  Speaker: Inhye E. Ahn, MD – Dana-Farber Cancer Institute
• 09:40 - 09:55 CEST

  How Do I Treat Double Refractory Patients with Targeted Therapy?
  

  Speaker: Lindsey E. Roeker, MD – CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center
• 09:55 - 10:10 CEST

  How Do I Treat Double Refractory Patients with Cellular Therapy?
  

  Speaker: Philip Thompson, MB, BS (Hons) – Peter MacCallum Cancer Centre & Royal Melbourne Hospital; The Sir Peter MaCallum Department of Clinical Oncology, University of Melbourne
• 10:10 - 10:25 CEST

  Panel Discussion With Interactivity and Audience Q&A
• 10:25 - 10:30 CEST

  Transcriptional reprogramming and survival co-dependencies of chronic lymphocytic leukemia resistant to venetoclax
  

  Primary Author / Presenter: Deepa Sampath, PhD – University of Texas MD Anderson Cancer Center
• 10:30 - 10:35 CEST

  A functional prognostic model predicts progression free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax
  

  Primary Author / Presenter: Sigrid S. Skånland, PhD – Oslo University Hospital
• 10:35 - 10:40 CEST

  Ten-year follow-up of a phase II study of ibrutinib in relapsed/ refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)
  

  Primary Author / Presenter: Aseel Alsouqi, MD – The Ohio State University